Introduction
OTS167 is a novel synthetic molecule undergoing clinical development as anticancer agent. It has been found to be a very potent inhibitor (IC 50 of 0.41 nM) (Chung et al., 2012) of maternal embryonic leucine zipper kinase (MELK), a protein kinase aberrantly upregulated in many types of cancer and essential for survival and proliferation of undifferentiated cancer cells (Ganguly et al., 2014) .
Glucuronidation is a common conjugation reaction catalyzed by UDPglucuronosyltransferase (UGT) enzymes. The reaction involves the transfer of glucuronic acid from UDP-glucuronic acid (UDPGA) to an acceptor substrate containing hydroxyl, carboxyl, amino or sulfhydryl groups to generate more polar and excretable compounds (Tukey and Strassburg 2000) . The human UGTs are classified into families UGT1 and UGT2, and subdivided into UGT1A, UGT2A and UGT2B subfamilies based on gene structure and sequence homology (Guillemette 2003) . The UGT1A enzymes are generated by alternative splicing of unique exons 1 to the common exons 2-5, whereas the UGT2Bs are individually transcribed. There are 9 UGT1As (UGT1A1, UGT1A3-UGT1A10), all of which are expressed in the gastrointestinal tract. UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6 and UGT1A9 are expressed in the liver, the major site of glucuronidation, whereas UGT1A7, UGT1A8 and UGT1A10 are extrahepatic Strassburg 2000 and Finel et al., 2005) . All 7 UGT2B enzymes (UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17 and UGT2B28) are found in the liver Strassburg 2000 and Lévesque et al., 2001 ). Many polymorphisms exist in the UGT genes (http://www.pharmacogenomics.pha.ulaval.ca/cms/ugt_alleles/; accessed Nov. 26, 2014) .
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UGT genetic variation could have a significant impact on metabolism of endogenous compounds such as bilirubin (Bosma 2003) , and on variability in response to drugs such as irinotecan among others .
The metabolism of OTS167 has not been previously described. The presence of phenolic and nitrogen-containing functional groups in its chemical structure (Fig. 1) suggested that the drug may undergo glucuronidation. In this study, we aimed to (1) evaluate whether OTS167 is glucuronidated in vitro by HLM, HIM and UGTs, (2) investigate the relationship between UGT polymorphisms and OTS167 glucuronidation in human livers, and (3) evaluate the potential inhibitory effects of OTS167 on glucuronidation reactions.
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Materials and Methods
Chemicals and reagents
OTS167 was provided by OncoTherapy Science, Inc. (Kawasaki City, Kanagawa, Japan).
Coumarin, 4-methylumbelliferone (4-MU), 4-methylumbelliferyl-β-D-glucuronide hydrate (4-MU-G), diclofenac sodium salt, sulfinpyrazone, imipramine, hecogenin, niflumic acid, emodin, potassium phosphate monobasic, β -glucuronidase (Type IX-A, from Escherichia coli) and DMSO were obtained from Sigma-Aldrich (St. Louis, MO).
Imipramine N-β-D glucuronide (imipramine-G) and nilotinib were purchased from Toronto Research Chemicals (North York, Ontario, Canada). UGT Reaction Mix Solution A (25 mM UDPGA) and Solution B (250 mM Tris-HCl, 40 mM MgCl 2 and 0.125 mg/ml alamethicin) were acquired from BD Biosciences (Bedford, MA).
Acetonitrile, methanol, formic acid, glacial acetic acid, ammonium acetate, 7-hydroxycoumarin and sodium phosphate monobasic and dibasic were purchased from Thermo Fisher Scientific (Hanover Park, IL).
Microsomal preparations
Normal human livers were obtained with human subjects' approval through the Liver Tissue Cell Distribution System (Pittsburgh, PA; NIH Contract #HHSN276201200017C) and the Cooperative Human Tissue Network. Human liver microsomes (HLM) were prepared using differential centrifugation methods (Ramírez et al., 2007) . Pooled human intestinal microsomes (HIM) and microsomes from cDNA-transfected baculovirus-insect cells (Supersomes   TM   ) expressing UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7,   UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and   DMD # 63271   7 UGT2B17 as well as UGT control microsomes were obtained from BD Gentest (Woburn, MA).
OTS167 glucuronidation assay
Experiments were conducted to study the linearity of OTS167 glucuronide (OTS167-G)
formation with respect to time and protein using pooled HLM and HIM. HIM, UGT1A7, UGT1A8 and UGT1A10), and processed as described above.
Calibration curves were linear over the concentration range of 0.31 to 10 µM (r 2 > 0.99).
OTS167 glucuronidation by expressed human UGT enzymes
To screen for OTS167 glucuronidation activity, enzymes expressed in the liver (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, UGT2B15 and UGT2B17) were incubated with 3.4 µM OTS167 (K m for HLM) for 30 min (optimum time for HLM). Extrahepatic UGTs (UGT1A7, UGT1A8 and UGT1A10)
were incubated for 35 min (optimum time for HIM) with 1.7 µM OTS167 (K m for HIM).
Protein concentration for all UGTs was 0.5 mg total protein/ml.
Enzyme kinetics in HLM, HIM and UGTs
Kinetic experiments with HLM, HIM and UGTs were performed as described above using 11 concentrations of OTS167 (range: 0.5 -100 µM).
Correlation studies in HLM
Incubations with 46 individual HLM (34 male, 12 female) were performed as described above and contained 3.4 µM OTS167. Measurements of glucuronidation activities toward thyroxine (UGT1A1 and UGT1A3 substrate) (Tong et al., 2007; Yamanaka et al., DMD # 63271 10 2007; Yoder Graber et al., 2007; Kato et al., 2008) , SN-38 (UGT1A1 substrate) (Iyer et al., 1998; Hanioka et al., 2001; Gagné et al., 2002) , mycophenolic acid (UGT1A9 substrate) (Bernard and Guillemette, 2004; Miles et al., 2005) and testosterone (UGT2B17 substrate) , and quantitation of mRNA levels (UGT1A1, UGT1A3, UGT1A9 and UGT2B17) in this set of HLM were previously described (Iyer et al., 1999; Yoder Graber et al., 2007; Ramírez et al., 2007; Kang et al., 2010; Liu et al., 2014) .
Inhibition of OTS167 glucuronidation
OTS167 glucuronidation by HLM, HIM and UGTs (UGT1A1, UGT1A3, UGT1A8, UGT1A9 and UGT1A10) was investigated in the presence of UGT inhibitors.
Incubations were performed as described above using OTS167 at the respective K m values (HLM: 3.4 µM; HIM: 1.7 µM; UGT1A1: 5.7 µM; UGT1A3: 2.2 µM; UGT1A8:
3.7 µM; UGT1A10: 0.9 µM) except for UGT1A9. Incubations with UGT1A9 were performed at 3.4 µM (K m for HLM) as its K m could not be estimated. Incubations included the following inhibitors: 2.5 μM nilotinib (dissolved in DMSO) for UGT1A1 (Ai et al., 2013) , 500 μM imipramine (in deionized water) for UGT1A3 (Lu at al., 2009 ), 2.5 μM niflumic acid (in DMSO) for UGT1A9 (Miners et al., 2011) , and 100 μM emodin (in DMSO) for UGT1A8 and UGT1A10 (Watanabe et al., 2002) . Control incubations contained vehicle (no inhibitor added). Total concentration of organic solvents in incubations was 1% (v/v).
Genotyping
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UGT polymorphisms significantly associated with UGT1A1 and UGT1A3 phenotypes (Jinno et al., 2003; Liu et al., 2014; Yamamoto et al., 1998 ) were genotyped as previously described (Innocenti et al., 2004; Liu et al., 2014) . These gene variants were the functional SNPs UGT1A1*28 (rs8175347, -53[TA] 6>7 , in the UGT1A1 promoter) and UGT1A1*6 (rs4148323, 211G>A, G71R, in UGT1A1 exon 1), and the tag SNPs (Liu et al., 2014) rs6706232 (UGT1A3 E27E), rs10203853 (in the UGT1A 3'-flanking region) and rs33979061 (in UGT1A1 intron 1).
Inhibition of UGTs by OTS167
4-MU glucuronidation
4-MU was used as non-specific substrate to evaluate the inhibitory potential of OTS167 on the majority of the UGTs (UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17). Incubations contained 4-MU (concentrations from Dong et al., 2012) , UGTs (concentrations reported by Liu et al., 2010 except that UGT1A10 was used at 0.25 mg/ml), 2.5 mM UDPGA, 50 mM Tris-HCl (pH 7.5), 8 mM MgCl 2 , 25 µg/ml alamethicin and OTS167 (0.4 μM, 2 μM and 10 μM). Incubation times for UGTs have been previously reported (Dong et al., 2012) . Positive controls for inhibition were 500 μM diclofenac (in DMSO) for UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15
and UGT2B17 , and 1 mM sulfinpyrazone (in DMSO) for UGT1A3 (Uchaipichat et al., 2006) . Negative (vehicle) controls contained methanol (OTS167 incubations) or DMSO (incubations with diclofenac and sulfinpyrazone). Organic solvent concentrations were kept at 1% (v/v). Incubations were stopped with 100 μl ice-DMD # 63271 12 cold acetonitrile containing 100 μΜ 7−hydroxycoumarin (internal standard). Samples were centrifuged (20,817 rcf, 15 min, 4°C) prior to analysis by HPLC (10 μl) as previously reported . 4-MU-G standards ranged from 1.25 μM to 100 μM.
Imipramine glucuronidation
Imipramine was used for investigation of the inhibitory effect of OTS167 on UGT1A4.
Incubations were performed as previously described with minor modifications. Reactions contained 2.5 mM UDPGA, 50 mM Tris-HCl (pH 7.5), 8 mM MgCl 2 , 25 µg/ml alamethicin, 500 μM imipramine, 0.5 mg/ml protein and OTS167 (0.4 μM, 2 μM and 10 μM) or hecogenin (200 μM in methanol as positive control for inhibition). The negative (vehicle) control contained 1% methanol. Reactions were stopped after 60 min with ice-cold acetonitrile containing 100 μΜ 7−hydroxycoumarin as internal standard, and centrifuged at 20,817 rcf for 15 min (4°C). Supernatants (10 μl)
were analyzed by HPLC. The mobile phase consisted of 28/72 (v/v) acetonitrile/10 mM potassium phosphate monobasic (pH 2.6) at a flow rate of 1 ml/min. Separation was achieved with a XTerra RP18 column (4.6 x 100 mm, 5 mm; Waters Corporation, Milford, MA) and a Nova-Pak C18 (4 μm) guard column (Waters Corporation, Milford, MA). UV detection (254 nm) was used. Imipramine-G standards ranged from 1.9 μM to 30 μM.
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To determine the mass and structure for OTS167-G, microsomes (1 mg/ml HLM, 0.5 mg/ml UGT1A1 and 0.5 mg/ml UGT1A8) were incubated with 10 µM OTS167 for 90 min as described above. The reaction was stopped with addition of 100 µL ice-cold acetonitrile, subjected to HPLC, and the metabolite peak (eluting around 13 min) was collected for mass spectrometry (MS). The latter was dried down under nitrogen gas, reconstituted in methanol, and subjected to MS using an API 2000 MS/MS triple quadruple system (Applied Biosystems, Foster City, CA). Additionally, OTS167 was considered statistically significant when p was less than 0.05. Data were analyzed using GraphPad Prism 6.00 for Windows (GraphPad Software, La Jolla, CA, www.graphpad.com) unless specified otherwise.
Results
Identification of OTS167-G in microsomal incubations
Incubations containing OTS167, UDPGA and HLM showed formation of a single product with a shorter retention time (12.7 min) than OTS167 (15.2 min) ( Fig. 2A) , suggesting formation of a metabolite that is more polar than its parent compound. The conjugated compound was absent from incubations without OTS167, UDPGA or microsomes (data not shown). Incubations with β-glucuronidase showed complete disappearance of the new peak (Fig. 2B) , proving that the metabolite formed is OTS167-
G. Same results were obtained in incubations with HIM (data not shown).
Enzyme kinetics in HLM and HIM
HLM and HIM exhibited substrate inhibition kinetics ( Fig. 3A and 3B ). Kinetic parameters are summarized in Table 1 . Both microsomal systems showed high affinity for the substrate (K m = 3.4 µM for HLM and 1.7 µM for HIM). The difference in intrinsic metabolic clearances (CL int ) for OTS167 by HLM and HIM was less than 2-fold.
Glucuronidation activity was inhibited with OTS167 concentrations higher than 25 µM (K i = 168 and 276 µM for HLM and HIM, respectively).
OTS167 glucuronidation by expressed human UGT enzymes
Incubations with UGT1A1, UGT1A3, UGT1A8, UGT1A9 and UGT1A10 showed formation of a single product with the same retention time as that observed with HLM and HIM. OTS167-G formation rates were 163 ± 4 pmol/min/mg, 95 ± 1 pmol/min/mg, 87 ± 1 pmol/min/mg, 33 ± 1 pmol/min/mg and 27 ± 2 pmol/min/mg for UGT1A1, DMD # 63271 16 UGT1A8, UGT1A3, UGT1A10 and UGT1A9, respectively (Fig. 4) . UGT1A4, UGT1A6, UGT1A7, UGT2B4, UGT2B7, UGT2B10, UGT2B15 and UGT2B17 microsomes did not metabolize OTS167.
Kinetic analyses in recombinant microsomes expressing human UGTs
Kinetic experiments were conducted with the UGTs that metabolized OTS167 in the screening experiments. However, kinetic parameters could not be estimated in experiments with UGT1A9 due to the low rate of metabolite formation. The substrate inhibition model best fit the kinetic data generated with UGT1A1, UGT1A3, UGT1A8
and UGT1A10. Representative kinetic profiles are shown for UGT1A1 (Fig. 3C ) and UGT1A8 (Fig. 3D ). UGT1A8 (72 µl/min/mg) and UGT1A1 (64 µl/min/mg) had the highest CL int for OTS167 followed by UGT1A3 (51 µl/min/mg) and UGT1A10 (47 µl/min/mg) ( Table 1) . These UGTs all showed high affinity for the substrate (K m = 0.9 -5.7 µM). OTS167-G formation was inhibited with substrate concentrations higher than 25 µM (UGT1A1, UGT1A3 and UGT1A8) or 10 µM (UGT1A10). K i values were high (range: 179 -428 µM).
Correlation of OTS167 glucuronidation with UGT activities and mRNA levels
OTS167-G formation was measured in 46 Caucasian HLM. The average rate of OTS167 glucuronidation (mean ± S.D.) was 100.7 ± 35.8 pmol/min/mg (range: 35.6 -195.2 pmol/min/mg). The interindividual variation in OTS167-G formation was 36%. Rates of OTS167 glucuronidation correlated strongly with thyroxine (r=0.91, p<0.0001) (Fig. 5A) and p<0 .0001) (Fig. 5B) mRNA levels was weak and insignificant (r=0.25, p=0.10).
Inhibition of OTS167 glucuronidation
The effect of chemical inhibitors was studied to confirm the UGTs involved in OTS167 glucuronidation. Results are shown in Fig. 6 . Nilotinib showed strong inhibitory effects on OTS167-G formation by UGT1A1 (83%) (Fig. 6A ) and HLM (68%) (Fig. 6B ), whereas inhibition of metabolism by HIM (25%) (Fig. 6B ) was modest. Imipramine was found to inhibit OTS167-G production by 45%, 34% and 19% in incubations with UGT1A3 ( Fig. 6A ), HLM and HIM (Fig. 6B) , respectively. In incubations with emodin, OTS167 glucuronidation was inhibited by 76%, 100%, 65% and 47% in incubations with UGT1A8 ( Fig. 6A) , UGT1A10 (Fig. 6A) , HLM ( Fig. 6B) and HIM (Fig. 6B) , respectively. Niflumic acid completely inhibited OTS167 glucuronidation in the presence of UGT1A9 (Fig. 6A) . Very low inhibition was found when coincubated with HLM (10%) and HIM (5%) (Fig. 6B) .
Association of OTS167 glucuronidation with genotypes
Reduced OTS167 glucuronidation rates were observed across UGT1A1*28, rs6706232 and rs33979061 genotypes; the opposite effect was observed with rs10203853 (Table 2) .
A modest and significant association was observed between rs6706232 genotypes and OTS167-G formation rates with G/G > G/A > A/A (p=0.03). A borderline association (p =0.05) was found with UGT1A1*28 (*1/*1 > *1/*28 > *28/*28). The differences in OTS167 glucuronidation rates among samples with rs33979061 and rs10203853 genotypes did not reach statistical significance (p>0.05).
To assess the effect of the UGT1A1*6 polymorphism on OTS167 glucuronidation, incubations were performed using HLM from a donor heterozygous for UGT1A1*6. Additional samples with UGT1A1*6 were not available. The OTS167-G formation rate was low (57.8 pmol/min/mg) compared to the average velocity (100.7
pmol/min/mg) in 46 Caucasian HLM (all G/G). This UGT1A1*6 carrier did not have the UGT1A1*28 mutation. The other genotypes (rs6706232, rs33979061 and rs10203853)
were not available.
Inhibition of UGTs by OTS167
To investigate whether OTS167 is a UGT inhibitor, we performed co-incubations of OTS167 with 4-MU (non-specific substrate for all UGTs except for UGT1A4 and UGT2B10) and imipramine (specific UGT1A4 substrate). OTS167 showed no to marginal inhibition (<15%) of UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT2B4, UGT2B7, UGT2B15 and UGT2B17 at all concentrations tested (range: 0.4 -DMD # 63271 19 10 μM) ( Fig. 7A and 7B ). Similar results were observed for UGT1A1 (0-7% inhibition with 0.4 and 2 μM OTS167), UGT1A7 (0-11% with 0.4 and 2 μM OTS167) and UGT1A10 (7% with 0.4 μM OTS167) (Fig. 7A) . At higher concentrations, relatively weak inhibition of UGT1A1 (36% with 10 μM OTS167), UGT1A7 (22% with 10 μM) and UGT1A10 (21% and 33% with 2 and 10 μM OTS167) was obtained (Fig. 7A ).
Residual activity (%) left after treatment with diclofenac, hecogenin and sulfinpyrazone (positive controls for inhibition) is shown in Table 3 .
Identification of OTS167-G by MS/MS
Based on the structure of OTS167, the metabolite could be either an O-glucuronide or an N-glucuronide. We hypothesize that the metabolite is an N-glucuronide due to the fragmentation patterns of the molecule in Q1 (Supplemental Fig. 1 
Discussion
This is the first in vitro study to report glucuronidation as a metabolic pathway involved in OTS167 clearance. We demonstrated that UGT1A1 and UGT1A3 are the major hepatic UGTs involved in OTS167 metabolism. Among these, UGT1A1 appears to play the main role based on our experimental data and its high level of hepatic and intestinal expression (Nakamura et al., 2008; Izukawa et al., 2009; Ohno et al., 2009; Wu et al., 2011; Court et al., 2012; Harbourt et al., 2012; Rowland et al., 2013) . Supporting data include high CL int for OTS167, significant correlations of OTS167 glucuronidation with UGT1A1 activity and mRNA levels in HLM, and high level of HLM inhibition with nilotinib, a highly selective UGT1A1 inhibitor at low concentrations (Ai et al., 2013) .
The decreased glucuronidation observed in HIM after treatment with nilotinib reflects inhibition of intestinal UGT1A1 and unaffected OTS167 glucuronidation activity by intestinal UGT1A8 and UGT1A10. We hypothesize that UGT1A3 is involved in OTS167-G formation to a lesser extent than UGT1A1 as the correlation between OTS167-G formation and UGT1A3 mRNA (r=0.36) was not as strong as with UGT1A1 mRNA (r=0.72), and UGT1A3 is expressed in the liver at lower levels than UGT1A1 (Nakamura et al., 2008; Izukawa et al., 2009; Ohno et al., 2009; Wu et al., 2011; Court et al., 2012; Harbourt et al., 2012; Rowland et al., 2013) . The high correlation observed between OTS167 and thyroxine glucuronidation (r=0.91) reflects contribution from both UGT1A1 and UGT1A3. Use of imipramine as a UGT1A3 inhibitor (Lu et al., 2009) confirmed its involvement in the glucuronidation reaction. However, we cannot draw conclusions regarding the extent of UGT1A3 involvement compared to UGT1A1 based on inhibition results, as even though imipramine reduced glucuronidation in HLM (34%) DMD # 63271 21 to a lesser extent than nilotinib (68%), the latter was a more efficient inhibitor of OTS167 glucuronidation (in UGT1A1 microsomes) than imipramine (for UGT1A3). The low inhibition of OTS167-G formation observed in HIM with imipramine is likely due to the lower expression of UGT1A3 in the intestines compared to UGT1A1, UGT1A8, and UGT1A10 (Nakamura et al., 2008; Ohno et al., 2009; Wu et al., 2011) . UGT1A9 seems to have a marginal role in OTS167 metabolism. This enzyme has high hepatic expression (Nakamura et al., 2008; Izukawa et al., 2009; Ohno et al., 2009; Wu et al., 2011; Court et al., 2012; Harbourt et al., 2012; Rowland et al., 2013 ) but it did not glucuronidate OTS167 at a significant extent, the correlations with UGT1A9-marker activity and mRNA levels were weak compared to the results with UGT1A1, and glucuronide production in HLM and HIM was weakly inhibited (5 -10%) by a very strong UGT1A9 inhibitor.
Since UGT1A8 and UGT1A10 are expressed in the intestine but not in the liver (Ohno, et al., 2009; Harbourt et al., 2012) , we hypothesize that these enzymes could contribute to first-pass drug metabolism after oral administration of OTS167. UGT1A8 had higher CL int for OTS167 than UGT1A10. Correlation studies could not be performed as individual HIM were not available. The inhibition of OTS167-G formation observed in HIM very likely reflects complete inhibition of UGT1A10, high inhibition of UGT1A8, and inhibition of UGT1A1 as this enzyme is highly expressed in the intestine (Ohno, et al., 2009; Wu et al., 2011; Court et al., 2012 , Harbourt et al., 2012 and emodin inhibited glucuronidation in HLM. Emodin is a good UGT1A8 and UGT1A10 inhibitor but is not highly selective (Yamanaka et al., 2007) .
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We hypothesize that OTS167 undergoes N-glucuronidation according to MS data.
Various nitrogen-containing compounds are converted to N-glucuronides, a reaction catalyzed by multiple enzymes including UGT1A1, UGT1A3, UGT1A4, UGT1A8, UGT1A9, UGT2B4, UGT2B7 and UGT2B10 (Kaivosaari et al., 2011) . This reflects the fact that aromatic heterocyclic substrates are structurally very diverse and UGTs involved in their glucuronidation are substrate-dependent (Kaivosaari et al., 2011) . Our hypothesized structure for OTS167-G includes three possible sites where the glucuronide molecule might attach to the amine. Further NMR studies will be required to confirm our results.
We also identified potential genotypic predictors of OTS167 glucuronidation.
The trends observed, although not always statistically significant, are in agreement with those previously observed with the UGT1A1 substrate SN-38: decreased glucuronidation activities with UGT1A1*28, rs6706232 and rs33979061, and increased glucuronide formation with rs10203853 (Liu et al., 2014) . However, as the associations of rs6706232
and UGT1A1*28 with OTS167-G formation rates were modest, the effect of these SNPs on OTS167 clearance may not be significant. UGT1A1*6, an allele present in Asians with a 13 -23% frequency (Guillemette 2003) , reduces the catalytic efficiency of UGT1A1 (Premawardhena et al., 2003) and predicts irinotecan-related toxicity in that population . We observed reduced OTS167 glucuronidation observed in a liver with UGT1A1*6. Additional studies are needed to evaluate its impact on OTS167-G formation in individuals of Asian ancestry.
It seems unlikely that OTS167 will have clinically significant effects on the glucuronidation of other drugs. The degree of relevance of the in vitro inhibition of DMD # 63271 23 UGT1A1 (36%) and UGT1A10 (33%) by 10 μM OTS167 is of no concern, and it is unlikely that significantly higher plasma concentrations will be maintained in patients. 
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